Ibrahim A.B.Alaraby Salem M.Fasih T.W.Brown A.Sakr T.M.Labeled Compounds DepartmentHot Labs CenterAtomic Energy AuthorityCairo13759Egypt; Pharmaceutical Chemistry DepartmentFaculty of PharmacyOctober University of Modern Sciences and Arts (MSA)GizaEgypt; Radioactive Isotopes and Generators DepartmentHot Laboratories CentreAtomic Energy AuthorityCairo13759Egypt; Department of ChemistryUniversity of AlbertaEdmontonCanada2020-01-092020-01-0920182365731https://doi.org/10.1007/s10967-018-6013-zPubMed ID :https://t.ly/6wyMBScopusMSA Google ScholarAbstract: Non-invasive molecular imaging techniques are accruing more interest in the last decades. Several radiolabelling elements have been FDA-approved and are currently used to characterize tumors. In this study, the DNA intercalating agent doxorubicin was radiolabelled with 125I. Several parameters for the radiolabelling reaction were investigated and optimized. A maximum yield of 94 � 0.3% was reached after reacting 20�?g of doxorubicin with 200�?g Chloramine-T at pH 5 for 30�min. The in vivo stability of 125I-doxorubicin is validated by the low propensity for thyroid uptake in mice. The preclinical T/NT ratio was approximately 6.4 at 30 min. Docking and molecular dynamics confirmed that the radiolabelling of doxorubicin did not affect (or slightly improved its binding to DNA). Overall, 125I-doxorubicin was demonstrated to be a promising non-invasive probe for solid tumor imaging. Graphical Abstract: [Figure not available: see fulltext.]. � 2018, Akad�miai Kiad�, Budapest, Hungary.EnglishDoxorubicinMolecular dockingMolecular dynamicsRadioidinationTumor imagingdoxorubicindoxorubicin i 125iodine 125tosylchloramide sodiumtracerunclassified druganimal experimentanimal modelanimal tissueArticleDNA drug complexEhrlich ascites tumorfemaleisotope labelingmolecular dockingmolecular dynamicsmolecular imagingmousenonhumanorgan distributionthyroid glandArticlehttps://doi.org/10.1007/s10967-018-6013-zPubMed ID :